#1 Clinical Trials Search in Europe

Bexmarilimab

Bexmarilimab, an innovative drug targeting the CLEVER-1 protein, is currently being studied in clinical trials for various types of cancer. These trials aim to assess its safety, tolerability, and potential effectiveness when used alone or in combination with other treatments. The studies focus on different cancer types, including renal cell carcinoma, colon cancer, non-small cell lung cancer, and hematological malignancies, offering hope for new treatment options in oncology.

Table of Contents

What is Bexmarilimab?

Bexmarilimab, also known as FP-1305, is a new investigational drug being studied for its potential in treating various types of cancer[2]. It is a type of medication called a monoclonal antibody, which is a laboratory-made protein designed to target specific cells in the body[2].

How Does Bexmarilimab Work?

Bexmarilimab works by targeting a protein called Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1)[2]. This protein is found on certain cells in the body and is thought to play a role in suppressing the immune system’s ability to fight cancer. By blocking CLEVER-1, bexmarilimab aims to activate the immune system, potentially leading to the elimination of cancer cells[2].

What Conditions Does Bexmarilimab Treat?

Bexmarilimab is being studied for its potential in treating several types of cancer, including:

  • Renal Cell Carcinoma: A type of kidney cancer[1]
  • Colon Cancer: Cancer that starts in the large intestine[1]
  • Non-Small Cell Lung Cancer (NSCLC): A common type of lung cancer[2]
  • Acute Myeloid Leukemia (AML): A type of blood cancer[3]
  • Chronic Myelomonocytic Leukemia (CMML): A rare blood cancer[3]
  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[3]

Current Clinical Trials

Bexmarilimab is currently being studied in several clinical trials:

  1. Neoadjuvant Treatment for Renal Cell and Colon Carcinoma: This study is investigating the use of a single dose of bexmarilimab before surgery in patients with localized kidney or colon cancer[1]. Neoadjuvant treatment means giving medication before the main treatment (in this case, surgery) to potentially improve outcomes.
  2. Combination Treatment for Non-Small Cell Lung Cancer: This trial is studying the safety and effectiveness of combining bexmarilimab with another immunotherapy drug called pembrolizumab in patients with advanced lung cancer[2].
  3. Treatment for Blood Cancers: This study is looking at the safety and potential effectiveness of bexmarilimab in combination with standard treatments for various blood cancers, including AML, CMML, and MDS[3].

How is Bexmarilimab Administered?

Bexmarilimab is typically administered through an intravenous (IV) infusion, which means it’s given directly into a vein[2][3]. The dosage and frequency of administration can vary depending on the specific clinical trial and the condition being treated. In some studies, it’s given every three weeks, while in others, it may be given weekly or every two weeks[2][3].

Potential Side Effects

As bexmarilimab is still in the investigational stage, all potential side effects may not be known. The clinical trials are designed to monitor for adverse events, which are any unfavorable and unintended signs, symptoms, or diseases that occur during the study[1][2][3]. These may include:

  • Infusion reactions
  • Nausea, vomiting, or diarrhea
  • Changes in blood cell counts
  • Fatigue

It’s important to note that not all patients will experience these side effects, and the severity can vary. The clinical trials are closely monitoring patients for any adverse events to ensure safety[2].

Future Prospects

The ongoing clinical trials aim to determine the safety, tolerability, and effectiveness of bexmarilimab in various cancer types. If these trials show promising results, it could lead to further studies and potentially new treatment options for patients with these cancers[1][2][3].

It’s important to remember that bexmarilimab is still an investigational drug, which means it has not yet been approved by regulatory agencies for general use. Patients interested in this treatment should discuss with their healthcare providers about the possibility of participating in clinical trials.

Aspect Details
Drug Name Bexmarilimab (also known as FP-1305)
Target CLEVER-1 (Common Lymphatic Endothelial and Vascular Endothelial Receptor-1)
Cancer Types Studied Renal Cell Carcinoma, Colon Cancer, Non-Small Cell Lung Cancer, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Administration Intravenous infusion
Combination Therapies Pembrolizumab, Azacitidine, Venetoclax
Primary Objectives Safety, Tolerability, Dose Determination, Preliminary Efficacy
Key Measurements Adverse Events, Dose Limiting Toxicities, Response Rates, Survival Rates
Trial Phases Phase I/II

FAQ

  • What is Bexmarilimab? Bexmarilimab is an investigational drug that targets the CLEVER-1 protein. It is a monoclonal antibody designed to activate the immune system and potentially lead to cancer elimination.
  • What types of cancer are being studied with Bexmarilimab? Clinical trials are investigating Bexmarilimab for various cancer types, including renal cell carcinoma, colon cancer, non-small cell lung cancer, and hematological malignancies such as myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia.
  • How is Bexmarilimab administered in these trials? Bexmarilimab is typically administered intravenously (through a vein) at different dose levels, depending on the specific trial. The frequency of administration varies, but it's often given every three weeks or in combination with other treatments.
  • What are the main goals of these clinical trials? The primary goals of these trials are to assess the safety and tolerability of Bexmarilimab, determine the appropriate dosage, and evaluate its potential effectiveness in treating various types of cancer, either alone or in combination with other treatments.
  • Are there any known side effects of Bexmarilimab? As with any investigational drug, the full range of side effects is still being studied. The trials are closely monitoring for adverse events, particularly those of Grade 3 or higher. Common side effects observed in cancer treatments may include fatigue, nausea, and changes in blood cell counts.

Ongoing Clinical Trials on Bexmarilimab

  • Study of Bexmarilimab plus Doxorubicin in Adults with Metastatic Soft Tissue Sarcoma

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study of Bexmarilimab Combined with Standard Treatment for Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

    Not recruiting

    1 1 1
    Investigated drugs:
    Finland

Glossary

  • CLEVER-1: Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, a protein targeted by Bexmarilimab to potentially activate the immune system against cancer cells.
  • Neoadjuvant: A treatment given before the main treatment, usually before surgery, to potentially shrink a tumor or prepare the body for the primary treatment.
  • Dose Escalation: A method in clinical trials where the dose of a drug is gradually increased to find the optimal balance between effectiveness and side effects.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects, determined during the dose escalation phase of a clinical trial.
  • Dose Limiting Toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug being tested in a clinical trial.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Pembrolizumab: A type of immunotherapy drug that works by blocking a protein called PD-1, helping the immune system recognize and attack cancer cells.
  • Azacitidine: A chemotherapy drug used to treat certain blood cancers by helping bone marrow produce normal blood cells and killing abnormal cells in the bone marrow.
  • Venetoclax: A targeted therapy drug that works by blocking a protein called BCL-2, which helps cancer cells survive. It's used in treating certain blood cancers.
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells.

References